News | November 05, 2021
Prime Therapeutics to list Semglee and Insulin Glargine
Biocon Biologics and Viatris co-developed the products
Biocon Biologics and Viatris co-developed the products
The combined entity will have 12 hospitals with 3,666 beds
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Second interchangeable biosimilar product approved by agency
The company claims that its Empagliflozin tablets are the most affordable in India
Subscribe To Our Newsletter & Stay Updated
